TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29937273

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins plus Ezetimibe
Number of subjects: 0
Study: 26866477

Group type: EXPERIMENTAL
Intervention: Incredible Years parenting intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Wait list control condition
Number of subjects: 136
Study: 25332468

Group type: EXPERIMENTAL
Intervention: Leu-enriched essential amino acids (3.5 g of Leu)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control essential amino acids (1.85 g of Leu)
Number of subjects: 15
Study: 22779280

Group type: EXPERIMENTAL
Intervention: 5 mm post length
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7 mm post length
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 9 mm post length
Number of subjects: 30
Study: 20482417

Group type: EXPERIMENTAL
Intervention: Methods involving self-poisoning, jumping or stabbing
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lower effectiveness of the DSH event to resolve the reasons for the event
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Any method other than superficial external injury to skin
Number of subjects: 70
Study: 18256393

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 160
Study: 16749353

Group type: EXPERIMENTAL
Intervention: Intermittent Peritoneal Dialysis (IPD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Haemodialysis (HD)
Number of subjects: 40
Study: 12514650

Group type: EXPERIMENTAL
Intervention: 1988 ACC/AHA guidelines for PTCA
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: 1993 ACC/AHA guidelines for PTCA
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: ACC/AHA guidelines for CABG
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: RAND guidelines for PTCA
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: RAND guidelines for CABG
Number of subjects: 1219
Study: 10489396

Group type: EXPERIMENTAL
Intervention: Fruit/vegetable diet
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Combination diet
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Combination diet in hypertensive subjects
Number of subjects: 354
Study: 8942358

Group type: EXPERIMENTAL
Intervention: Liquid diet followed by feeding every 20 min (fed state)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Liquid diet followed by fasting (fasted state)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 15NH4Cl taken orally every 20 min for 6 h (total 1.5 g)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 4
Study: 1656145

Group type: EXPERIMENTAL
Intervention: Sodium valproate (1600 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GABA (10(‐8)‐10(‐5) M)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Muscimol (GABAA agonist, 10(‐8)‐10(‐5) M)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Baclofen (GABAB agonist, 10(‐8)‐10(‐5) M)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bicuculline (GABAA antagonist)
Number of subjects: 10
Study: 6203300

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pseudo-acupuncture
Number of subjects: 25

Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 25
Study: 27831829

Group type: EXPERIMENTAL
Intervention: ViSC Social Competence Program
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1377
Study: 29995794

Group type: EXPERIMENTAL
Intervention: High-energy ESWT (0.210 mJ/mm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-energy ESWT (0.068 mJ/mm)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both high-energy and low-energy ESWT
Number of subjects: 30
Study: 27658839

Group type: EXPERIMENTAL
Intervention: Inpatient psychotherapy (N=21) including eye movement desensitization and reprocessing (EMDR)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Outpatient clinical management (N=17)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison between inpatient psychotherapy and outpatient clinical management
Number of subjects: 38
Study: 24508417

Group type: EXPERIMENTAL
Intervention: Fentanyl Ethypharm (FE)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 21963069

Group type: EXPERIMENTAL
Intervention: Ultrathin colonoscope (UTC)
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Standard colonoscope (SC)
Number of subjects: 1121
Study: 19759186

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with concurrent chemotherapy
Number of subjects: 742

Group type: COMPARATOR
Intervention: Preoperative radiotherapy without concurrent chemotherapy
Number of subjects: 742
Study: 17913002

Group type: EXPERIMENTAL
Intervention: 0.3% Zinc + 0.025% Chlorhexidine mouthrinse
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control formulations (various enzymes and antibacterial agents)
Number of subjects: 10
Study: 17348891

Group type: EXPERIMENTAL
Intervention: PRP plus autologous bone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Autologous bone
Number of subjects: 16
Study: 15003976

Group type: EXPERIMENTAL
Intervention: Intrathecal antitetanus immunoglobulin
Number of subjects: 120
Study: 10796930

Group type: EXPERIMENTAL
Intervention: Exercise prior to imaging (1 minute of arm swinging)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No exercise (preexercise imaging)
Number of subjects: 41
Study: 9106921

Group type: EXPERIMENTAL
Intervention: Conformal treatment with customized blocks, median high-dose volume (HDV) of 689 cm3
Number of subjects: 266

Group type: COMPARATOR
Intervention: Conventional treatment with rectangular fields, median high-dose volume (HDV) of 792 cm3
Number of subjects: 266
Study: 8258043

Group type: EXPERIMENTAL
Intervention: Etidronate 10 mg/kg/day
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 3700590

Group type: EXPERIMENTAL
Intervention: Slide-tape counseling format
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group counseling format
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Individual counseling format
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Audiovisual counseling format
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Genetic counseling overall
Number of subjects: 61
Study: 31296516

Group type: EXPERIMENTAL
Intervention: Surgical stabilisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 0
Study: 28738258

Group type: COMPARATOR
Intervention: Chemotherapy alone (n=80)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (n=74)
Number of subjects: 154
Study: 25642663

Group type: EXPERIMENTAL
Intervention: Auditory event-related potentials (AERP) measures
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Neonatal brain damage
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Neonatal morbidity
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gestational age and brain damage
Number of subjects: 70
Study: 23213105

Group type: EXPERIMENTAL
Intervention: Adjuvant whole-brain radiotherapy (WBRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 0
Study: 21241286

Group type: EXPERIMENTAL
Intervention: Perpetrator's group with a norm to be unkind
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perpetrator's group with a norm to be kind
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target's group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third party group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19285200

Group type: EXPERIMENTAL
Intervention: Bone Mineral Density (BMD) testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osteoporosis risk-assessment tools (e.g., WHO fracture-risk algorithm)
Number of subjects: 0
Study: 16254147

Group type: EXPERIMENTAL
Intervention: High-dose DAT (daunorubicin, cytarabine, and thioguanine)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Standard-dose DAT (daunorubicin, cytarabine, and thioguanine)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Consolidation with CsA
Number of subjects: 418

Group type: COMPARATOR
Intervention: Consolidation without CsA
Number of subjects: 418
Study: 14501959

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study: 10716478

Group type: EXPERIMENTAL
Intervention: Aspirin (200 mg per day) with oral anticoagulants (OAC)
Number of subjects: 229

Group type: COMPARATOR
Intervention: OAC alone
Number of subjects: 229
Study: 9322479

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg plus droperidol 1.25 mg (Group D2)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg plus metoclopramide 10 mg (Group M2)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg plus granisetron 40 micrograms/kg (Group G2)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Droperidol 1.25 mg (Group D1)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg (Group M1)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Granisetron 40 micrograms/kg (Group G1)
Number of subjects: 270
Study: 1534256

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g per day of 85% EPA and DHA)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Corn oil (6 g per day)
Number of subjects: 156
Study: 3884224

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg twice a day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sulindac (200 mg twice a day)
Number of subjects: 8
Study: 30394347

Group type: EXPERIMENTAL
Intervention: Lidocaine with dexmedetomidine (2 μg/mL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (1:100,000 dilution)
Number of subjects: 52
Study: 29873874

Group type: EXPERIMENTAL
Intervention: Super-mini percutaneous nephrolithotomy (SMP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 160
Study: 27707855

Group type: EXPERIMENTAL
Intervention: Verbal and model (hearing, sight, and touch)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Verbal and video (hearing and sight)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Verbal (hearing)
Number of subjects: 67
Study: 24496455

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC)
Number of subjects: 6045

Group type: COMPARATOR
Intervention: Non-users of oral anticoagulants
Number of subjects: 6045

Group type: EXPERIMENTAL
Intervention: OAC with antiplatelets (aspirin or clopidogrel)
Number of subjects: 6045
Study: 23028549

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (Sangvia group)
Number of subjects: 216

Group type: COMPARATOR
Intervention: No use of autologous blood (Control group)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Sangvia group
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Sangvia group and Control group
Number of subjects: 216
Study: 20332729

Group type: EXPERIMENTAL
Intervention: Yoga exercises
Number of subjects: 26

Group type: COMPARATOR
Intervention: Classic osteoporosis exercise program
Number of subjects: 26
Study: 17541109

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 177
Study: 15200742

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.5% vaginal gel (CHX-VG), 2.5 g, daily for 7 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Metronidazole vaginal tablets 500 mg (M), daily for 7 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clotrimazole (CL) vaginal cream, daily for 7 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.5% vaginal gel (CHX-VG)
Number of subjects: 90
Study: 11270911

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 308
Study: 9692706

Group type: EXPERIMENTAL
Intervention: Omeprazole (mean duration 5.7 years, range 0.7-12.5 years)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Histamine H2-antagonists (9 patients)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: No drugs (11 patients)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Any gastric antisecretory drug (mean duration 10.1 years, range 0.7-21 years)
Number of subjects: 109
Study: 8204331

Group type: EXPERIMENTAL
Intervention: Guidelines sent to 30 practices in the intervention group
Number of subjects: 170

Group type: COMPARATOR
Intervention: No guidelines (control group)
Number of subjects: 170
Study: 3659736

Group type: EXPERIMENTAL
Intervention: Late bath + placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Early bath
Number of subjects: 6
Study: 29901296

Group type: EXPERIMENTAL
Intervention: 5-reductase inhibitor (5-ARI) Pentester 5 mg once daily
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: -blocker Fokusin 0.4 mg once a day
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combination therapy with 5-ARI (Penester 5 mg once daily) and blocker (Fokusin 0.4 mg once daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Monotherapy (either Pentester or Fokusin)
Number of subjects: 67
Study: 25496338

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 24103254

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (60 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate and MDMA (combined)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 0
Study: 23241145

Group type: EXPERIMENTAL
Intervention: WBA/active management advice
Number of subjects: 3851

Group type: EXPERIMENTAL
Intervention: Physiotherapy package of up to six sessions
Number of subjects: 3851

Group type: COMPARATOR
Intervention: Usual care advice (UCA)
Number of subjects: 3851

Group type: COMPARATOR
Intervention: Single session of advice from a physiotherapist
Number of subjects: 3851
Study: 20123670

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (120 mg EGb 761 twice daily)
Number of subjects: 3069

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3069
Study: 17187496

Group type: EXPERIMENTAL
Intervention: Estrogen as an adjunct to standard antipsychotic medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antipsychotic medication
Number of subjects: 0
Study: 15713726

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Combination therapy with alendronate and hormone replacement therapy
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 12016085

Group type: EXPERIMENTAL
Intervention: Shock wave therapy (1000 impulses at 14 kV)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham procedure (control group)
Number of subjects: 43
Study: 10560786

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol (50 microg/day, transdermal) and norethisterone acetate (2.5 mg/day, orally)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol
Number of subjects: 200
Study: 8919710

Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 to 800 mg, mean 683 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 1871801

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0

Group type: COMPARATOR
Intervention: CsA and steroids alone
Number of subjects: 0
Study: 6355851

Group type: EXPERIMENTAL
Intervention: Free care
Number of subjects: 3958

Group type: COMPARATOR
Intervention: Insurance plans requiring patient to pay a share of medical bills
Number of subjects: 3958
Study: 31271526

Group type: COMPARATOR
Intervention: Etanercept alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept and methotrexate in combination
Number of subjects: 0
Study: 28841667

Group type: EXPERIMENTAL
Intervention: D-aspartic acid (6 g/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: D-aspartic acid and Placebo
Number of subjects: 22
Study: 25903259

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Healthy Eating diet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both diet groups
Number of subjects: 120
Study: 24856802

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (PCON), n=49
Number of subjects: 101

Group type: COMPARATOR
Intervention: Primary angioplasty alone (non-PCON), n=52
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (PCON) in swine model, n=6
Number of subjects: 101

Group type: COMPARATOR
Intervention: Primary angioplasty alone (non-PCON) in swine model, n=6
Number of subjects: 101
Study: 22992377

Group type: EXPERIMENTAL
Intervention: Placebo treatment (disguised as a hypnotic) for one week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warning about one bogus side effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warning about four bogus side effects
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study: 19776136

Group type: EXPERIMENTAL
Intervention: Cocoa powder with 500 mL skim milk/d (C+M)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Only 500 mL skim milk/d (M)
Number of subjects: 42
Study: 17305650

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg daily)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (600 mg vitamin E, 250 mg vitamin C and 20 mg beta‐carotene daily)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Both aspirin and antioxidant vitamins
Number of subjects: 366

Group type: COMPARATOR
Intervention: Neither treatment (control group)
Number of subjects: 366
Study: 15355623

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (EPN)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 107
Study: 10685992

Group type: EXPERIMENTAL
Intervention: Surfactant lavage followed by partial liquid ventilation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gas ventilation with surfactant lavage
Number of subjects: 12

Group type: COMPARATOR
Intervention: Partial liquid ventilation alone
Number of subjects: 12
Study: 9285285

Group type: EXPERIMENTAL
Intervention: Sferics exposure (10 kHz-sferic, 50 nT, 500 microseconds, 10 minutes duration, pulse repetition rate 7-20 Hz)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sferics exposure in subjects with high weather sensitivity, somatic complaints, and neuroticism
Number of subjects: 20
Study: 8279224

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen exposure (2.8 atm, 100% O2, 60 min daily for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air exposure (control group)
Number of subjects: 0
Study: 3519240

Group type: EXPERIMENTAL
Intervention: 0.085 mg/kg bambuterol b.i.d.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.170 mg/kg bambuterol b.i.d.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.34 mg/kg bambuterol b.i.d.
Number of subjects: 19

Group type: COMPARATOR
Intervention: 0.071 mg/kg terbutaline t.i.d.
Number of subjects: 19
Study: 3291897

Group type: EXPERIMENTAL
Intervention: Pinacidil or hydralazine as monotherapy or with propranolol and/or hydrochlorothiazide
Number of subjects: 121
Study: 30626597

Group type: EXPERIMENTAL
Intervention: MOVI-KIDS intervention (three 60 min sessions/week from October 2013 to May 2014)
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: MOVI-KIDS intervention
Number of subjects: 1434
Study: 31519288

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (1-hour class, twice a week for 12 weeks, plus 30-minutes home practice three times per week)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (maintained usual daily activities)
Number of subjects: 35
Study: 28164396

Group type: EXPERIMENTAL
Intervention: 5α-reductase inhibitors (5-ARIs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Untreated)
Number of subjects: 20
Study: 26607669

Group type: EXPERIMENTAL
Intervention: PERC-based strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23243167

Group type: EXPERIMENTAL
Intervention: Dried Distillers Grains Plus Solubles (DDGS)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Corn Silage-Based Soybean Meal (CSBM)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Corn Gluten Feed (CGF)
Number of subjects: 198
Study: 20490671

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Open surgical treatment
Number of subjects: 54
Study: 18309613

Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composite (FRC) layer at the adhesive interface
Number of subjects: 60

Group type: COMPARATOR
Intervention: No fiber-reinforced composite (FRC) layer at the adhesive interface
Number of subjects: 60
Study: 16817617

Group type: EXPERIMENTAL
Intervention: Fuzzy logic applied to diffusion tensor images of the human spinal cord
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional fractional anisotropy index
Number of subjects: 0
Study: 12621507

Group type: EXPERIMENTAL
Intervention: Oral valacyclovir 500 mg twice daily until resolution of neutropenia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral acyclovir 600 mg every 6 h until resolution of neutropenia or acyclovir 125 mg/m(2) intravenously every 6 h
Number of subjects: 60